FINWIRES · TerminalLIVE
FINWIRES

伍德賽德能源公司報告第一季產量下降，強勁的液化天然氣需求支撐了銷售。

By

-- 伍德賽德能源公司（WDS）週三公佈了第一季財報，數據顯示，該季度總產量為4,520萬桶油當量/日，低於去年同期的4,910萬桶油當量/日。 該公司表示，截至3月31日的第一季度，天然氣日均產量為15.78億標準立方英尺，低於去年同期的18.41億標準立方英尺/日。 該公司稱，第一季液體產量日均22.1萬桶，略低於去年同期的22.3萬桶/日。 該公司表示，西澳大利亞的營運受到颶風影響和季節性因素的干擾，導致產量下降。 伍德賽德補充道，該季度總銷量達5,170萬桶油當量/日，高於去年同期的5,030萬桶油當量/日。 該公司表示，天然氣日均銷量為20.16億立方英尺（MMscf/d），高於去年同期的19.68億立方英尺/日；液體銷量也從21.3萬桶/日增至21.8萬桶/日。 伍德賽德能源公司預計全年產量為1.72億桶油當量/日至1.86億桶油當量/日，維持先前的預期；資本支出預計為40億至45億美元。 該公司表示，斯卡伯勒能源項目已完成96%，並預計在2026年第四季交付首批液化天然氣。浮式生產裝置安裝完畢後，調試工作正在進行中。 伍德賽德能源公司表示，特里恩計畫已完成56%，目標是在2028年實現首次產油。該項目包括開發24口海底油井，預計將支持未來的產量成長。 該公司表示，路易斯安那州液化天然氣計畫已完成24%，其中一號生產線已完成31%，預計2029年交付首批液化天然氣貨物。 該公司還表示，其位於博蒙特的新氨廠已於2月完成首批氨貨物的交付，並於3月接管營運。

Price: $23.72, Change: $+0.46, Percent Change: +1.98%

Related Articles

Research

Research Alert: CFRA Downgrades Rating To Sell From Hold On Shares Of Essex Property Trust, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target by $15 to $250 using a narrower equity risk premium and a forward P/FFO of 15.5x, which is in line with the multifamily residential REIT average. We keep our 2026 FFO estimate at $16.15 and lower 2027's by $0.05 to $16.45 on respective revenue projections of $1.94B and $1.98B. Rental revenue is not yet rebounding to historical growth levels. Across the industry, we are seeing inflation in key operating expenses exceeding revenue growth, and this leads to modest gains in cash NOI growth Y/Y. We expect these market conditions to continue as pricing power for ESS and its peers seems to have eased. In particular, ESS has a West Coast portfolio profile that is exposed to significant job layoffs in the technology sector. In our opinion, we have not yet seen the tail risk of major announcements just released in recent weeks. ESS has the challenge of complying with strict housing guidelines in California, leading to the trust historically underperforming peers in other parts of the country.

$ESS
Research

Research Alert: CFRA Keeps Buy Rating On Shares Of Biogen Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $236, 13.8x our new 2027 EPS view, a discount to BIIB's five-year historical forward P/E average of 14.1x. We lower our 2026 EPS view to $15.24 from $16.14 to adjust for the impact from acquired IPR&D. We keep our 2027 EPS view at $17.16. BIIB reported a strong start to 2026, with sales of $2.5B and adjusted EPS of $3.57. We see a successful stabilization of the business after years of decline, due to a 12% Y/Y increase in the growth products portfolio. In our view, during the analyst call, management presented a clear strategic vision centered on the pending $5.6B acquisition of Apellis, expected to close in Q2, which can transform BIIB into a growth company by adding two commercial assets, Syfovre and Empaveli. We think the Apellis deal could bridge a revenue gap until 2028, when the company's late-stage pipeline matures. Via this acquisition, BIIB also gains nephrology expertise and an established infrastructure, which could set its key asset Felzartamab launch for success.

$BIIB
Australia

Starbucks to Sustain Sales Momentum; to Focus on Margins in H2, UBS Says

Starbucks (SBUX) is expected to maintain solid sales momentum on its turnaround strategy, though investor focus is shifting toward margin recovery in H2, UBS said in a note on Wednesday.The brokerage said strong transaction-driven comparable sales growth in Q2 reflected improvements in operations, menu innovation and updated loyalty program.Looking ahead, UBS said continued execution on initiatives such as afternoon beverage platforms, loyalty enhancements, store closures and operational improvements should support sales into H2.UBS also expects margin expansion later in the year, supported by sales leverage, cost savings and easing pressures from tariffs and coffee costs.UBS raised the price target on the stock to $105 from $100 but maintained a neutral rating.Price: $106.10, Change: $+8.82, Percent Change: +9.06%

$SBUX